Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A high-quality meta-analysis of 7 RCTs with 6,517 patients showing consistent survival and response benefit for chemoimmunotherapy, but with quantified and clinically relevant toxicity trade-offs that require individualised patient selection.
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
A narrative review synthesizing evidence on gastric atrophy staging and risk stratification to inform clinical surveillance strategy and serological monitoring in individual patients.
A sound retrospective cohort study with internal and external validation showing that high BMI predicts superior immunotherapy outcomes in esophageal cancer, but limited by observational design, modest sample size, and reliance on surrogate endpoints rather than hard clinical outcomes.
Large national cohort study with hard clinical outcome (overall survival) showing inferior outcomes with dose de-escalation, aligning with recent randomized evidence and supporting current standard-of-care dosing.
A single case report with clinical narrative describing an unusual metastatic pattern; it raises mechanistic hypotheses and clinical management questions but provides no comparative data, control group, or generalizable evidence.
Rigorous population-based retrospective cohort study with multivariable adjustment comparing four treatment strategies in localized oral cavity cancer, demonstrating significantly improved survival with elective neck dissection versus omission or radiotherapy alone.
Network meta-analysis of 36 RCTs with 8925 patients comparing defined treatment classes for resectable locally advanced gastric cancer, with consistent superiority of chemotherapy plus immunotherapy across survival and pathological endpoints, but limited by indirect comparisons and heterogeneous trial populations.